Sponsored Lunch and Learn Presentation*
11:30PM – 1:00 PM | Friday, February 18, 2022
Speaker: Shintaro Ichikawa, Ph.D., Director of Technical Affairs
Session Description: Postbiotics are an emerging category of health and wellness ingredients. In this talk, we will introduce the function of specific postbiotics, the clinical research behind unique strains for IMMUSE™ and EYEMUSE™ and the latest breakthrough approach in immunity. Join this session to hear about IMMUSE™, awarded the Frost & Sullivan New Product Innovation in the immune health ingredient industry and EYEMUSE™, the first postbiotic for eye health.
1. The unique mechanism of action of IMMUSE™, Lactococcus lactis strain Plasma (LC-Plasma) and the importance of plasmacytoid dendritic cells within the immune system.
2. The interconnection of immune health & eye health, how a new innovative ingredient, EYEMUSE™ can stimulate immune cells to support eye health.
3. Understand the functional and clinically studied health benefits and formulation advantages of novel postbiotics.
About The Speakers:
Dr. Shintaro Ichikawa is the Director of Technical Affairs at Kyowa Hakko USA, leading the launch of the company’s unique Lactococcus lactis strain plasma, IMMUSE™, in the United States. Dr. Ichikawa led the launch of IMMUSE™ in Japan previously. Dr. Ichikawa received his doctorate in life science from the University of Tokyo, Department of applied biochemistry. Prior to joining Kyowa Hakko USA in 2019, Dr. Ichikawa served as the Manager of Corporate Strategy and Principal Investigator for Kirin Holdings, where he was responsible for the company’s research and development laboratory for over ten years. Having studied at the La Jolla Institute for Immunology at the University of San Diego as a visiting scientist, Dr. Ichikawa developed a keen interest and expertise in the immune health sector with a particular emphasis on delivering benefits via innovative delivery formats and based on the microbiome.
*Denotes a Non-CME activity.